Related Experiment Video

Updated: Feb 28, 2026

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
09:56

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

Published on: April 30, 2019

9.7K

Cabozantinib for the treatment of kidney cancer

Ahmed Abdelaziz1, Ulka Vaishampayan1

  • 1a Department of Oncology , Wayne State University/Barbara Ann Karmanos Cancer Institute , Detroit , MI , USA.

Expert Review of Anticancer Therapy
|June 22, 2017
PubMed
Abstract

Insights

Cabozantinib is an effective treatment for advanced renal cell carcinoma (RCC), improving progression-free survival and overall survival. This tyrosine kinase inhibitor shows promise in various patient groups and settings for RCC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cabozantinib is a tyrosine kinase inhibitor initially studied for medullary thyroid cancer.
  • It is now approved for metastatic renal cell carcinoma (RCC) post-first-line therapy.

Purpose of the Study:

  • To review the mechanism of action, pharmacodynamics, and pharmacokinetics of cabozantinib.
  • To discuss the development of cabozantinib for advanced RCC.
  • To explore its potential in specific patient populations and the current treatment landscape.

Main Methods:

  • Review of the METEOR trial comparing cabozantinib with everolimus in advanced RCC.
  • Analysis of the CABOSUN trial evaluating cabozantinib versus sunitinib in first-line metastatic RCC.
  • Examination of preclinical and clinical data on cabozantinib's efficacy and safety.

Main Results:

  • METEOR trial showed significantly improved response rates, progression-free survival, and overall survival with cabozantinib.
  • CABOSUN trial demonstrated improved progression-free survival with cabozantinib in untreated metastatic RCC patients.
  • Cabozantinib exhibits activity in specific subgroups, including poor-risk patients and those with bone metastases.

Conclusions:

  • Cabozantinib is a valuable therapeutic option for advanced RCC, offering significant survival benefits.
  • Its unique mechanism of action suggests potential for other malignancies.
  • Further research is warranted to optimize its use in diverse patient populations and treatment settings.
Keywords:
CABOSUNCabozantinibMETMETEORRCCrenal cell carcinomatargeted therapy

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
691
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
596